Technology ID
TAB-2696
Novel Rift Valley Fever Virus Vaccines
E-Numbers
E-254-2013-2
Lead Inventor
Bird, Brian (CDC)
Co-Inventors
Albarino, Cesar (CDC)
Nichol, Stuart (CDC)
Ksiazek, Thomas (CDC)
Applications
Vaccines
Therapeutics
Research Materials
Diagnostics
Consumer Products
Therapeutic Areas
Infectious Disease
Development Stages
Pre-Clinical (in vitro)
Development Status
- In vitro data available
- In vivo data available (animal)
Research Products
Research Equipment
Lead IC
CDC
ICs
CDC
This invention relates to recombinant Rift Valley fever (RVF) viruses containing deletions in one or more virulence genes. The recombinant RVF viruses, generated using a plasmid-based reverse genetics system, can be used as vaccines to prevent RVF infection in livestock and humans. The recombinant RVF viruses grow to high titers, provide protective immunity following a single injection, and allow for the differentiation between vaccinated animals and animals infected with wild-type RVF virus. Additionally, this technology relates to a method of using reverse genetics to generate recombinant RVF viruses.
Commercial Applications
- Rift Valley fever (RVF) virus vaccine development or improvement
- Prevention of RVF virus infection in livestock and humans
- Biodefense, biosecurity
Competitive Advantages
- In vivo evidence shows single-dose protection
- Allows for discrimination between vaccinated and naturally-infected subjects
- Useful for controlled screening of therapeutic compounds
Licensing Contact: